Neuronetics posts narrower Q3 loss as revenue climbs 12.5% and confirms 2026 outlook
+1 new source since this summary was written
Neuronetics reported third‑quarter 2026 revenue of $42.0 million, up 12.5% year‑over‑year, driven by a 20.1% rise in Greenbrook clinic sales. The company’s net loss narrowed to $1.7 million, or $0.02 per share, compared with a $9.0 million loss a year earlier, and adjusted EBITDA turned positive at $1.9 million. It also submitted a 510(k) for an accelerated TMS protocol and entered a partnership with Wave Neuro to explore PTSD treatment. Full‑year revenue guidance remains $160 million‑$164 million.
Why it matters
The narrower loss and positive adjusted EBITDA suggest improving profitability, which may support the stock’s recent price gain. The reaffirmed revenue range and higher gross‑margin outlook give investors clearer expectations for the remainder of 2026.
Key facts
- 1Q3 2026 total revenue was $42.0 million, a 12.5% increase from $37.3 million in the prior year. stocktitan.net
- 2Greenbrook clinic revenue grew 20.1% to $26.2 million. stocktitan.net
- 3Net loss for the quarter was $1.7 million, or $0.02 per share, versus a $9.0 million loss, $0.13 per share, a year earlier. rttnews.com
- 4Adjusted EBITDA improved to $1.9 million from a loss of $4.7 million a year ago. stocktitan.net
- 5Gross margin rose to 52.2% from 45.9% year‑over‑year. rttnews.com
- 6Full‑year 2026 revenue guidance is $160 million‑$164 million, unchanged from prior guidance. stocktitan.net
Summary written by AlphAI AI Desk from 5 of 5 sources. Not investment advice. Figures are as stated by the linked sources.